The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The potential role of anti-hemojuvelin agents for managing anemia in myelofibrosis
In this video, Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the potential role of DISC-0974 and other anti-hemojuvelin agents for the management of myelofibrosis (MF)-associated anemia, highlighting that these drugs may help to address the unmet need of patients with MF and anemia who do not respond to currently available therapies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so drugs like DISC-0974 and other drugs that do target that hemojuvelin pathway, you know, certainly, if proven to be beneficial, can impact the treatment of myelofibrosis quite positively. And the fact that, you know, we have drugs available, we have ESAs, we have Luspatercept, we have Danazol, but they don’t work all the time, right? If you look across all these drugs and across all the studies, roughly a third, maybe a little bit closer to 40% of patients will have an anemia benefit...
Yeah, so drugs like DISC-0974 and other drugs that do target that hemojuvelin pathway, you know, certainly, if proven to be beneficial, can impact the treatment of myelofibrosis quite positively. And the fact that, you know, we have drugs available, we have ESAs, we have Luspatercept, we have Danazol, but they don’t work all the time, right? If you look across all these drugs and across all the studies, roughly a third, maybe a little bit closer to 40% of patients will have an anemia benefit. And again, the challenge with this is it’s always so multifactorial, the causes of anemia. So we need lots of different approaches to this. And by kind of targeting this pathway a little bit more intensely, a little more continuously, we hope to increase the response rate, at least for those whose anemia is driven primarily by inflammation and elevated hepcidin levels. This is a complement to all the other strategies that we’re using to treat myelofibrosis-associated anemia.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
